[99mTc]Tc-labeled HYNIC conjugated chlorambucil as a tumor targeting Agent: Synthesis, characterization and ex-vivo evaluation

Soumi Kolay, Naveen Kumar, Mohini Guleria and Tapas Das

Bioorganic & Medicinal Chemistry Letters, 2024, 105, 129730
DOI: 10.1016/j.bmcl.2024.129730

In Vitro Assessment of 177Lu-Labeled Trastuzumab-Targeted Mesoporous Carbon@Silica Nanostructure for the Treatment of HER2-Positive Breast Cancer

Ayça Tunçel, Simone Maschauer, Olaf Prante and Fatma Yurt

Pharmaceuticals, 2024, 17, 732
DOI: 10.3390/ph17060732

Synthesis and comparative evaluation of 177Lu-labeled PEG and non-PEG variant peptides as HER2-targeting probes

Amit Kumar Sharma, Rohit Sharma, Kusum Vats, Haladhar Dev Sarma, Archana Mukherjee, Tapas Das and Drishty Satpati

Sci Rep, 2022, 12
DOI: 10.1038/s41598-022-19201-9

Advances in functional radionuclide imaging and therapy for individualized management of patients: the growing importance of Nuclear Theranostics in Precision Oncology Practice

Parth Baberwal and Sandip Basu

Expert Review of Precision Medicine and Drug Development, 2025, 10, 56
DOI: 10.1080/23808993.2025.2589524

India's Growing Nuclear Medicine Infrastructure and Emergence of Radiotheranostics in Cancer Care: Associated Challenges and the Opportunities to Collaborate

Baljinder Singh, Ghanshyam Sahani, Vikas Prasad, Ankit Watts and Rakesh Kumar

Indian Journal of Nuclear Medicine, 2023, 38, 201
DOI: 10.4103/ijnm.ijnm_77_23

Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes

Xinlin Liu, Yunlong Song, Panpan Cheng, Bing Liang and Dongming Xing

Cancer Treatment Reviews, 2024, 130, 102826
DOI: 10.1016/j.ctrv.2024.102826

Preparation of 177Lu‐PSMA‐617 in Hospital Radiopharmacy: Convenient Formulation of a Clinical Dose Using a Single‐Vial Freeze‐Dried PSMA‐617 Kit Developed In‐House

Mohini Guleria, Jeyachitra Amirdhanayagam, Haladhar D. Sarma, Ramya Priya Rallapeta, V. S. Krishnamohan, Ajit Nimmagadda, Parthasarathy Ravi, Sailaja Patri, Tekchand Kalawat, Tapas Das and Pierfrancesco Franco

BioMed Research International, 2021, 2021
DOI: 10.1155/2021/1555712

Advances and future directions in radiopharmaceutical delivery for cancer treatment

Sikander Ailawadhi, Deanna Pafundi and Jennifer Peterson

Expert Review of Anticancer Therapy, 2025, 25, 351
DOI: 10.1080/14737140.2025.2472859

Synthesis and Evaluation of [177Lu]Lu-Labeled-NLS-Trastuzumab Conjugate for Targeting of HER2 Positive Metastatic Breast Cancer: Evaluating the Effect on Intracellular Localization

Soumi Kolay, V. Kusum Vats, Rohit Sharma, Mohini Guleria, Jeyachitra Amirdhanayagam, Naveen Kumar, Manoj Kumbhakar, Archana Mukherjee and Tapas Das

ACS Med. Chem. Lett., 2025, 16, 2138
DOI: 10.1021/acsmedchemlett.5c00472

[225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts

Misaki Kondo, Zhongli Cai, Conrad Chan, Nubaira Forkan and Raymond M. Reilly

EJNMMI radiopharm. chem., 2023, 8
DOI: 10.1186/s41181-023-00208-0

GRPR-targeting radiotheranostics for breast cancer management

Alice D’Onofrio, Swantje Engelbrecht, Tilman Läppchen, Axel Rominger and Eleni Gourni

Front. Med., 2023, 10
DOI: 10.3389/fmed.2023.1250799

In vitro and in vivo evaluation of anti-HER2 antibody conjugates labelled with 225Ac

Kateřina Ondrák Fialová, Lukáš Ondrák, Martin Vlk, Ján Kozempel, Kateřina Nováková, Zbyněk Nový, Katarína Hajduová, Marián Hajdúch, Miloš Petřík, Marek Pruszynski, Frank Bruchertseifer and Alfred Morgenstern

EJNMMI radiopharm. chem., 2025, 10
DOI: 10.1186/s41181-025-00337-8

Development of Antibody and Antibody Fragment-Based Radiopharmaceuticals for Cancer Imaging and Therapy

Chi Soo Kang

Nucl Med Mol Imaging, 2025
DOI: 10.1007/s13139-025-00969-3

Tumor homing dextran and curcumin derived amphiphilic functional polymer self-assembling to tubustecan nanoarchitectures: A strategy of adorning the golden spice (curcumin) for taming the red devil (Dox)

Manita Das, Apeksha Joshi, Ranjitsinh Devkar, Sriram Seshadri and Sonal Thakore

Journal of Drug Delivery Science and Technology, 2022, 76, 103666
DOI: 10.1016/j.jddst.2022.103666

Dynamic Light Scattering for Assessing Aggregation in [177Lu]Lu-DOTA-Trastuzumab: A Quality Control Approach for Radioimmunotherapy

Huu Bao Nguyen, Aran Kim, Muhammad Zeeshan, Thuy Tien Nguyen, Gyeong-Tak Byeon, Jeong Eun Lim, Min-Kyoung Kang, Kanghyuk Choi and Jeongsoo Yoo

Bioconjugate Chem., 2026, 37, 450
DOI: 10.1021/acs.bioconjchem.5c00651

Clinical Dose Preparation of [ 177 Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [ 177 Lu]LuCl 3 for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression

Sreeja Raj Menon, Arpit Mitra, Avik Chakraborty, Megha Tawate, Sudeep Sahu, Sutapa Rakshit, Sujay Gaikwad, Geetanjali Dhotre, Archana Damle and Sharmila Banerjee

Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 384
DOI: 10.1089/cbr.2021.0230

PET receptor imaging in breast cancer

Ismet Sarikaya

Clin Transl Imaging, 2023, 12, 5
DOI: 10.1007/s40336-023-00601-4

Single Chelator–Minibody Theranostic Agents for89Zr PET Imaging and177Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer

Khanh-Van Ho, David S. Tatum, Lisa Watkinson, Terry Carmack, Fang Jia, Alessandro Mascioni, Charles A. Maitz, Darren Magda and Carolyn J. Anderson

J Nucl Med, 2024, 65, 1435
DOI: 10.2967/jnumed.124.267667

Improvement of End-of-Synthesis Radiochemical Purity of 177Lu-DOTA-PSMA-Ligands with Alternative Synthesis Approaches: Conversion Upswing and Side-Products Minimization

Anton Larenkov, Iurii Mitrofanov and Marat Rakhimov

Pharmaceutics, 2024, 16, 1535
DOI: 10.3390/pharmaceutics16121535

Effectiveness of [67Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer

Jessica Pougoue Ketchemen, Fabrice Ngoh Njotu, Hanan Babeker, Stephen Ahenkorah, Anjong Florence Tikum, Emmanuel Nwangele, Nikita Henning, Frederik Cleeren and Humphrey Fonge

Eur J Nucl Med Mol Imaging, 2024, 51, 2070
DOI: 10.1007/s00259-024-06648-3

Radiobioconjugate of Kadcyla with Radioactive Gold Nanoparticles for Targeted Therapy of HER2-Overexpressing Cancers

Kinga Żelechowska-Matysiak, Kamil Wawrowicz, Mateusz Wierzbicki, Tadeusz Budlewski, Aleksander Bilewicz and Agnieszka Majkowska-Pilip

Mol. Pharmaceutics, 2025, 22, 4019
DOI: 10.1021/acs.molpharmaceut.5c00288

Development and evaluation of 177Lu-imatinib: radiolabeling and cell culture studies

Emre Ozgenc, Merve Karpuz, Gunnur Guler, Zeynep Burak, Yücel Başpınar and Evren Atlıhan Gundogdu

Radiochimica Acta, 2025, 113, 899
DOI: 10.1515/ract-2025-0043

Complete Remissions of HER2-Positive Trastuzumab-Resistant Xenografts Using a Potent [225Ac]Ac-Labeled Anti-HER2 Antibody–Drug Radioconjugate

Jessica Pougoue Ketchemen, Fabrice Ngoh Njotu, Hanan Babeker, Alissar Monzer, Emmanuel Nwangele, Anjong Florence Tikum, Nikita Henning, Nava Hassani, Sarah Frye, Randy Perron, Chris Byrne, Candice Didychuk, Qi Qi, Laura Bannister, Alireza Doroudi and Humphrey Fonge

Clinical Cancer Research, 2025, 31, 685
DOI: 10.1158/1078-0432.CCR-24-1779

Radioligand–Antibody Conjugates: Integrating Antibody Engineering, Chelator Chemistry, and Radioligands for Precision Theranosis

Prakash Y. Khandave, Pravin U. Gudavalekar, Tapas Das and Abhay H. Pande

Mol Diagn Ther, 2026, 30, 259
DOI: 10.1007/s40291-025-00825-2

In Vivo Studies of [161Tb]Tb-Trastuzumab Radiopharmaceutical Therapy in Human Epidermal Growth Factor Receptor 2–Expressing Breast Tumors Show High Tumor Uptake and Tumor Growth Suppression

Sigrid Cold, Pragalath Sadasivam, Mette M. Wessel, Myrto Ischyropoulou, Jesper Fonslet, Trine B. Engel, Carsten H. Nielsen, Andreas Kjaer and Lotte K. Kristensen

J Nucl Med, 2026, jnumed.125.269741
DOI: 10.2967/jnumed.125.269741

Formulation of patient dose of [177Lu]Lu‐Trastuzumab using in‐house developed freeze‐dried kit: A path forward for clinical translation

Jeyachitra Amirdhanayagam, Mohini Guleria, Rohit Sharma, Naveen Kumar, Archana Mukherjee and Tapas Das

Labelled Comp Radiopharmac, 2024, 67, 131
DOI: 10.1002/jlcr.4086